Vaccines for Enteric Diseases

6-8 November 2013, The Royal Orchid Sheraton Hotel & Towers, Bangkok, Thailand

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 6th October

07.30am onwards
VED 2013 Registration

SESSION 1:
BURDEN & EPIDEMIOLOGY

Moderators:
Carl Mason (AFRIMS, Bangkok, Thailand)
Duncan Steele (Bill & Melinda Gates Foundation, Seattle, Washington, USA)

09.00-09.10
‘Welcome & Opening Address’
Supamit Chunsuttiwat (Ministry of Public Health, Bangkok, Thailand)

09.10-09.40
‘Aetiology and burden of diarrheal disease in Africa and Asia: GEMS’
Myron M. Levine (University of Maryland, Baltimore, Maryland, USA)

09.40-10.00
‘Epidemiology of enteric infections and consequences for child development in 8 resource poor communities in the developing world’
Dennis Lang (MAL-ED Network/NIH, Bethesda, Maryland, USA)

10.00-10.20
‘Use of the TaqMan array cards for multiple enteropathogens’
James Platts-Mills, Jie Liu, Rashidul Haque, Anita Zaidi, Esto Mduma, Jean Gratz and Eric Houpt (University of Virginia, Charlottesville, Virginia, USA)

10.20-10.40
‘Surveillance and immunomonitoring of Shigella natural infection towards vaccine development and evaluation’

Dani Cohen, Shiri Meron-Sudai, Adi Behar, Amit Hochberg, Anya Bialik, Ravit Bassal, Sophy Goren, Michal Perry-Markovich, Tamy Shohat and Shai Ashkenazi (Tel Aviv University, Tel Aviv, Israel)

10.40-11.00
Coffee Break & Poster Set-Up

SESSION 2:
ETEC VACCINES – UPDATES ON CLINICAL TRIALS

Moderators:
John Clements (Tulane University, New Orleans, Louisiana, USA)
Ann-Mari Svennerholm (University of Gothenburg, Gothenburg, Sweden)

11.00-11.20
‘Introduction: Implications of ETEC genomics for vaccine development’
Ann-Mari Svennerholm (University of Gothenburg, Gothenburg, Sweden)

11.20-11.40
‘Safety and immunogenicity of a single, oral dose of recombinant double-mutant heat-labile toxin (dmLT) derived from enterotoxigenic Escherchia coli (ETEC)’
Wilbur H. Chen, Samur S. El-Kamary, Mitchell B. Cohen, A. Louis Bourgeois, Lillian Van De Verg, Nicole Bauers, Mardi Reymann and Marcela F. Pasetti (University of Maryland, Baltimore, Maryland, USA)

11.40-12.00
‘Excellent safety and immunogenicity of a complete tetravalent oral inactivated whole cell ETEC vaccine tested with and without dmLT adjuvant demonstrated in a placebo-controlled Phase I study’
Anna Lundgren, J. Adamson, L. Bourgeois, N. Carlin, J. Clements, B. Gustafsson, M. Hartford,
J. Holmgren, J. Kaim, S. Koster, M. Lofstrand , M. Petzold, J. Tobias, R. Walker, G. Wiklund and A.-M. Svennerholm (University of Gothenburg, Gothenburg, Sweden)

12.00-12.20
‘Evaluation of a lyophilized formulation of enterotoxigenic Escherchia coli (ETEC) ACE527 vaccine administered alone or with a double-mutant E. coli heat-labile toxin (dmLT) in healthy adult subjects’
Clayton Harro, David Sack, Subhra Chakraborty, Barbara DeNearing, A. Louis Bourgeois, Michael Darsley, Alicia Marcum, Denise Adams, Len Dally, Nicole Bauers, Alan Fix and Richard Walker (The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA)

12.20-12.40
‘Preclinical investigation of novel antigens for ETEC vaccines’

James Fleckenstein, Qingwei Luo, Pardeep Kumar, Alaullah Sheikh, Timothy Vickers and Firdausi Qadri (Washington University School of Medicine, St. Louis, Missouri, USA)

12.40-13.00
‘Prevalence of toxin types and CFs of ETEC strains in Bangladesh for vaccine development’
Firdausi Qadri (ICDDR, Dhaka, Bangladesh)

‘Phase I clinical evaluation of adhesin-based ETEC vaccines’
Ramiro Gutierrez, M. Riddle, C. Porter, M. Maciel, S. Poole, R. Laird, M. Lane, G. Turiansky, A. Jarell, A. Castellano and S. Svarino (Naval Medical Research Center, Silver Spring, Maryland, USA)

13.00-14.00
Lunch Break & Posters

SESSION 3:
TYPHOID VACCINES

Moderators:
Chris Nelson (Sabin Vaccine Institute, Washington DC, USA)
Mike Levine (University of Maryland, Baltimore, Maryland, USA)

14.00-14.20
‘Epidemiology and genomics of typhoid fever – Mapping of the distribution of drug resistance in S. typhi and S. paratyphi
Gordon Dougan (Wellcome Trust Sangar Institute, Cambridge, UK)

14.20-14.40
‘Phase 1 and 2 trial of live, oral Salmonella enterica Serovar Paratyphi A vaccine harbouring mutations in guaBA and cipX
Karen L. Kotloff, Marcelo B. Sztein, Debbie-Ann T. Shirley, Marcela F. Pasetti, Sofie Livio, Christopher Vindurampulle, James Galen, and Myron M. Levine (University of Maryland, Baltimore, Maryland, USA)

14.40-15.00
‘Cross protection mediated by live attenuated non-typhoidal Salmonella vaccine strains’
Sharon M. Tennant, Jin-Yuan Wang, Patrick Schmidlein, Deanna Toema, Girish Ramachandran,
Mary A. Boyd, Raphael Simon, James E. Galen, Marcela Pasetti and Myron M. Levine (University of Maryland, Baltimore, Maryland, USA)

15.00-15.20
‘Bharat Biotech's Typbar-TCV™ (Vi-TT): New generation typhoid conjugate vaccine for the ones who need it most’
B.N. Patnaik, V. Krishna Mohan, R. Venkatesan, K. Gopinathan and Anit Singh (Bharat Biotech International, Hyderabad, India)

15.20-15.35
‘Estimation of typhoid cost of illness in developing countries’
Vittal Mogasale, B. Maskery, Y.E. Kim, R.L. Ochiai and T.F. Wierzba (International Vaccine Institute, Seoul, Republic of Korea)

15.35-15.50
‘The typhoid fever surveillance program in Africa programme (TSAP)’
Florian Marks, L.M. Cruz Espinoza, V. Kalckreuth, U. Panzer, S.E. Park, M. Ali, G.D. Pak, J. Im, F. Konings, J. May, H. Schutt-Gerowitt and T.F. Wierzba (International Vaccine Institute, Seoul, Republic of Korea)

15.50-16.05
‘Predicting the potential impact of typhoid vaccination in South Asia’
Virginia Pitzer (Yale School of Public Health, New Haven, Connecticutt, USA)

16.05-16.20
‘Development of a typhoid fever protein capsular matrix vaccine (PCMV) candidate’
Kevin Killeen (Matrivax Inc., Boston Masachusetts, USA)

16.20-16.40
Tea Break & Posters

SESSION 4:
FRONTIERS IN ENTERIC VACCINE DEVELOPMENT

Moderator: Fred Cassels (NIAID/NIH, Bethesda, Maryland, USA)

16.40-17.00
‘Oral formulations for vaccines against enteric diseases’
Dexiang Chen and Manjari Lal (PATH, Seattle, Washington, USA)

17.00-17.20
‘Targeting aminopeptidase N. an intestinal receptor of F4+ ETEC in the pig’
Eric Cox, Ph. Bellot, V. Melkebeek, B. Devriendt and B.M. Goddeeris (University of Gent, Gent, Belgium)

17.20-17.40
‘New integrated multidisciplinary systems oriented approach to improved Salmonella vaccines’
Pietro Mastroeni (University of Cambridge, Cambridge, UK)

17.40-18.00
‘Towards a protein-based vaccine against ETEC and Shigella
G. Renauld-Mongenie, P. Chaux, B. Guy, M. Gregory, M. Maciel Jr., P. Erlich, R. Kaminski, P. Dinadayala, M. Garinot, D. Poncet, Y. Liu, S. Poole, M. Riddle, A. Phalipon, F.X. Weill, T. Pierson, E. Oaks, P. Sansonetti and S. Savarino (Sanofi Pasteur, Marcy l’Etoile, France)

18.00-18.20
‘Development of a novel oral typhoid-ETEC vaccine’
Rocky Cranenburgh (Prokarium Ltd, Keele, UK)

18.20-18.40
‘Temperature-stablized, acid resistant Ty21a-vectored oral enteric fever-shigellosis vaccine: Advances in development’
Dennis J. Kopecko (Protein Potential LLC, Rockville, Maryland, USA)

18.40-19.00
‘Non-typhoidal Salmonella (NTS) core O-polysaccharide (COPS) conjugated to the homologous flagellin as candidate vaccines for protection against invasive NTS infections’
Raphael Simon, Sharon M. Tennant, Jin Y. Wang, Robert K. Ernst, Marcella Pasetti, Andrew Lees, James E. Galen and Myron M. Levine (University of Maryland, Baltimore, Maryland, USA)

19.00
VED 2013 Poster Session

 

VED 2013 Delegates

Login details will be supplied after you have registered for the event.

VED 2013 Venue


VED 2013 Sponsors

  • University of Tampere Vaccine Research Center
  • Retroscreen Virology
  • Crucell
  • PATH
  • Takeda
  • Mucosis
  • Intercell
  • Matrivax
  • Reagensia
  • Thailand Convention & Exhibition Burea
  • Novartis Vaccines
  • Sanofi Pasteur
  • UMN
  • BioVAXX
  • Nature Gene Therapy
  • DNAvaccine.com
  • Aldevron
  • Aridis Pharmaceuticals
  • GlaxoSmithKline Biologicals

VED 2013 Downloads

VED 2013 Leaflet

VED 2013 Mailing List

Name
E-mail Address
What is 1+4-2?